Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani

2021, Vol: 12, Issue: 3

12 / 3Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

« Previous Article

Review Article

SRP. 2021; 12(3): 207-212

doi: 10.31838/srp.2021.3.34

Crosstalk Between Sirt1 Activators And Nf-Îšb Axis As A Therapeutic Target To Reduce Pancreatic Cancer

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani.

Abstract
The cellular availability of NAD+ is essential for Sirtuin 1 (SIRT1), a class III histone deacetylase, catalytic activity which make it as a reliable metabolic sensor. For evidence, SIRT1 had a high expression in tissue with metabolic activity including muscle, brain, liver, pancreas, and adipose tissue. Previous reports have documented the crosstalk between SIRT1 and nuclear factor kappa-B (NF-ÎºB) signaling in conditions such as lymphoma, leukemia, and myeloma. The purpose of present study is to find the relationships between SIRT1 and NF-ÎºB activation on pancreatic cancer cells (Capan-2, AsPC-1, and BxPC-3). We found the activation of NF-ÎºB was inhibited by use 1 µM SIRT1 aptamer by increased the activity of SIRT1 protein. Overall, our findings suggested that SIRT1 activation resulting in inhibition of pancreatic cancer cells growth and significantly repression of NF-ÎºB proteins activation, this activation of SIRT1 by aptamer may be considered as a potential future therapy for cancer especially pancreatic cancer.

Key words: SIRT1, NF-ÎºB p65 Transcription Factor, Pancreatic Cancer.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Marwah Saad Joudah Articles by Inam Sameh Arif Articles by Basma Talib Al-Sudani
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani. Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer. SRP. 2021; 12(3): 207-212. doi:10.31838/srp.2021.3.34

Web Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani. Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer. http://www.sysrevpharm.org/?mno=51635 [Access: February 25, 2021]. doi:10.31838/srp.2021.3.34

AMA (American Medical Association) Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani. Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer. SRP. 2021; 12(3): 207-212. doi:10.31838/srp.2021.3.34

Vancouver/ICMJE Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani. Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer. SRP. (2021), [cited February 25, 2021]; 12(3): 207-212. doi:10.31838/srp.2021.3.34

Harvard Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani (2021) Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer. SRP, 12 (3), 207-212. doi:10.31838/srp.2021.3.34

Turabian Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani. 2021. Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer. Systematic Reviews in Pharmacy, 12 (3), 207-212. doi:10.31838/srp.2021.3.34

Chicago Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani. "Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer." Systematic Reviews in Pharmacy 12 (2021), 207-212. doi:10.31838/srp.2021.3.34

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Marwah Saad Joudah, Inam Sameh Arif, Basma Talib Al-Sudani (2021) Crosstalk Between Sirt1 Activators And Nf-Κb Axis As A Therapeutic Target To Reduce Pancreatic Cancer. Systematic Reviews in Pharmacy, 12 (3), 207-212. doi:10.31838/srp.2021.3.34

Contact Information

<submissions.srp@gmail.com

How to cite this article

Copyright © 2019 Systematic Reviews in Pharmacy All Rights Reserved. Subject to change without notice from or liability to Systematic Reviews in Pharmacy.

Copyright © 2021 Systematic Reviews in Pharmacy All Rights Reserved. Subject to change without notice from or liability to Systematic Reviews in Pharmacy. For best results, please use Internet Explorer or Google Chrome	Contact Information <submissions.srp@gmail.com